ArticleJournal of medical microbiology2016
Naegleria fowleri after 50 years: is it a neglected pathogen?
Article in Journal of medical microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 65 citations in OpenAlex.
- The outbreak of amoebic meningoencephalitis in Kerala: A wake-up call.The Indian journal of medical research · 2025Article
- Article
- Pediatric non-congenital central nervous system infections: role of imaging in the emergency department.Pediatric radiology · 2025Review
- Identification of Naegleria fowleri antigens recognized by serum antibodies from people of Mexicali Valley, México.Parasitology research · 2025Article
- Article
- A primary amoebic meningoencephalitis case suspected to be infected by indoor swimming, China, 2024.Frontiers in medicine · 2025Article
- The Pathology of the Brain Eating AmoebaIndian journal of microbiology · 2024Article
- Approaches for TargetingPathogens (Basel, Switzerland) · 2024Review
- Lactoferrin and Lysozyme Inhibit the Proteolytic Activity and Cytopathic Effect ofPathogens (Basel, Switzerland) · 2024Article
- Emerging patents versus brain eating amoebae,Pharmaceutical patent analyst · 2024Review
- Detection and Confirmation ofJournal of parasitology research · 2024Article
- Identification and genotyping ofParasite epidemiology and control · 2023Article
- Two MP2CL5 Antigen Vaccines from Naegleria fowleri Stimulate the Immune Response against Meningitis in the BALB/c Model.Infection and immunity · 2023Article
- Marine Meroterpenoids Isolated fromPharmaceuticals (Basel, Switzerland) · 2023Article
- Role of cathepsin B of Naegleria fowleri during primary amebic meningoencephalitis.Parasitology research · 2022Article
- Distribution and Current State of Molecular Genetic Characterization in Pathogenic Free-Living Amoebae.Pathogens (Basel, Switzerland) · 2022Review
- Zinc Oxide Nanoconjugates against Brain-Eating Amoebae.Antibiotics (Basel, Switzerland) · 2022Article
- Genotyping and Molecular Identification of Acanthamoeba Genotype T4 and Naegleria fowleri from Cerebrospinal Fluid Samples of Patients in Turkey: Is it the Pathogens of Unknown Causes of Death?Acta parasitologica · 2022Article
- A Fluorometric Assay for theMicrobiology spectrum · 2022Article
- Real-Time PCR Confirmation of a Fatal Case of Primary Amoebic Meningoencephalitis in Turkey Caused by Naegleria fowleri or Brain-Eating Amoeba.Acta parasitologica · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
It has been 50 years since the first case of primary amoebic meningoencephalitis (PAM), an acute and rapidly fatal disease of the central nervous system (CNS), was reported in Australia. It is now known that the aetiological agent of PAM is Naegleria fowleri, an amoeba that is commonly known as 'the brain-eating amoeba'. N. fowleri infects humans of different ages who are in contact with water contaminated with this micro-organism. N. fowleri is distributed worldwide and is found growing in bodies of freshwater in tropical and subtropical environments. The number of PAM cases has recently increased, and the rate of recovery from PAM has been estimated at only 5 %. Amphotericin B has been used to treat patients with PAM. However, it is important to note that there is no specific treatment for PAM. Moreover, this amoeba is considered a neglected micro-organism. Researchers have exerted great effort to design effective drugs to treat PAM and to understand the pathogenesis of PAM over the past 50 years, such as its pathology, molecular and cellular biology, diagnosis and prevention, and its biological implications, including its pathogenic genotypes, its distribution and its ecology. Given the rapid progression of PAM and its high mortality rate, it is important that investigations continue and that researchers collaborate to gain better understanding of the pathogenesis of this disease and, consequently, to improve the diagnosis and treatment of this devastating infection of the CNS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.